Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB.
de Steenwinkel, Jurriaan E.M.
ten Kate, Marian T.
de Knegt, Gerjo J.
Aarnoutse, Rob E.
Boeree, Martin J.
Verbrugh, Henri A.
van Soolingen, Dick
Bakker-Woudenberg, Irma A.J.M.
|Publication:||Name: Emerging Infectious Diseases Publisher: U.S. National Center for Infectious Diseases Audience: Academic; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2012 U.S. National Center for Infectious Diseases ISSN: 1080-6040|
|Issue:||Date: April, 2012 Source Volume: 18 Source Issue: 4|
|Product:||Product Code: 2834850 Tuberculostatic Preparations; 2830000 Drugs & Pharmaceuticals; 2834000 Pharmaceutical Preparations; 2834190 Metabolic Agents; 2834199 Metabolic Agents NEC; 8000120 Public Health Care; 9005200 Health Programs-Total Govt; 9105200 Health Programs NAICS Code: 325412 Pharmaceutical Preparation Manufacturing; 3254 Pharmaceutical and Medicine Manufacturing; 62 Health Care and Social Assistance; 923 Administration of Human Resource Programs; 92312 Administration of Public Health Programs SIC Code: 2834 Pharmaceutical preparations|
The emergence of Mycobacterium tuberculosis resistance to
antituberculosis (anti-TB) drugs is a major public health challenge that
is threatening World Health Organization targets set for the elimination
of TB (1). Approximately 500,000 cases of multidrug-resistant TB (MDR
TB) are diagnosed annually, but the true magnitude of the MDR TB problem
is not known because adequate laboratory tools are lacking. Multiple
factors contribute to low cure rates, treatment failures, and relapses:
poor-quality guidance regarding treatment, HIV co-infection,
transmission of resistant forms of TB, underdeveloped laboratory
services, and unavailability of alternative drug treatments. However,
the evolution of M. tuberculosis is an additional factor that presumably
fuels the worldwide problem of emerging resistance. The Beijing genotype
is significantly associated with drug resistance (2,3), especially in
geographic areas where prevalence of resistance to anti-TB drugs is
high, and it is associated with recent TB transmission (2-6). There are
also indications that the population structure of M. tuberculosis in
areas with a high prevalence of anti-TB drug resistance is changing
rapidly toward an increase in Beijing genotype strains (2,6-8).
The World Health Organization target rates for detecting and curing TB in Vietnam have been met; however, the rate of TB infection is not decreasing as expected (4,5). Earlier in this country, the Beijing genotype was strongly correlated with MDR TB and treatment failures (9). Extensive molecular epidemiologic studies showed that the Beijing and East-African/Indian (EAI) genotypes are predominating in Vietnam; each lineage causes [approximately equal to] 40% of the TB cases. According to the single-nucleotide polymorphism typing described by Hershberg et al. (10), the Beijing genotype is a representative of the modern lineage, and the EAI genotype is believed to represent an evolutionary lineage more closely related to the common ancestor of the M. tuberculosis complex.
We compared the in vitro activity of anti-TB drugs against susceptible Beijing and EAI M. tuberculosis isolates from Vietnam and determined the in vitro mutation frequency of these strains during drug exposure. We also determined time-kill kinetics of anti-TB drugs and assessed the emergence of resistant mutants and the concentration range within which resistant mutants and no susceptible mycobacteria were selected. The concentration at which resistant mutants did not emerge (the mutant prevention concentration) was also ascertained. By using this approach, we established an in vitro model for determining differences in the ability of M. tuberculosis strains to resist anti-TB drug treatment.
Results of a liquid culturing system (BD BACTEC MGIT 960 System; BD Diagnostics, Sparks, MD, US) (for details, see the online Technical Appendix, wwwnc. cdc.gov/EID/pdfs/11-0912-Techapp.pdf) showed that all 5 Beijing and 5 EAI genotype strains were susceptible to isoniazid (INH), rifampin (RIF), moxifloxacin (MXF), and amikacin (AMK). MICs were determined by using the agar proportion method (11), which showed that ranges were small for the Beijing and EAI genotype strains: INH, 0.062-0.125 mg/L; RIF, 0.125-1 mg/L; MXF, 0.125-0.5 mg/L; and AMK, 0.5-2 mg/L. Duplicate values showed only minor differences.
We determined the mutation frequencies of the Beijing and EAI genotype strains by using previously defined critical drug concentrations of 1 mg/L for INH, RIF, and MXF and 5 mg/L for AMK (11,12) (for details, see the online Technical Appendix). The mutation frequencies of the Beijing and EAI genotype strains were similar for INH, MXF, and AMK, but they were significantly different for RIF (1.6 x [10.sup.-5] to 5.4 x [10.sup.-3] for Beijing strains vs. 6.3 x [10.sup.-8] to 3.8 x [10.sup.-4] for EAI strains; p = 0.003, unpaired Mann-Whitney test) (Table 1; Figure 1). Because rifamycin drugs are widely used to treat TB, the difference in the mutation frequencies of Beijing and EAI genotype strains for RIF is a major finding.
For Beijing genotype strains, the increase in mutation frequency during exposure to RIF could be due to described missense mutations in the mut genes (13). Such mutations in the mut genes can change the DNA repair mechanism; as a consequence, the frequency of resistant mutant formation might increase. However, a direct correlation between the occurrence of particular mutations in mut genes and altered mutation frequency has not been proven. Furthermore, Werngren and Hoffner (14) found an equal mutation frequency for Beijing (3.6 x [10.sup.-8)] and non-Beijing (4.4 x [10.sup.-8)] genotypes. A possible explanation for the discrepancy in findings might be the concentration of RIF used in the subculture plates. In our study, the critical concentration of 1 mg/L RIF was used (11), whereas Werngren and Hoffner used a concentration of 2 mg/L RIF. In addition, Werngren and Hoffner compared the Beijing and non-Beijing genotypes of several genotype families, whereas we compared Beijing and EAI genotype strains that were selected from the same tuberculosis-endemic area and during the same period.
We determined the time-kill kinetics of RIF toward 2 strains with significantly different mutation frequencies: Beijing-1585 (3.7 x [10.sup.-3] [3.0 x [10.sup.-3] and 4.3 x [10.sup.-3,] duplicates]) and EAI-1627 (3.5 x [10.sup.-6] [2.8 x [10.sup.-6] and 4.1 x [10.sup.-6], duplicates]). Cultures with low and high densities of Beijing-1585 and EAI-1627 were investigated as described (15). RIF showed strong time- and concentration-dependent activity toward low-density cultures of the 2 strains (Figure 2). Low concentrations of RIF were needed to achieve [greater than or equal to] 99% mycobacterial killing; differences between Beijing-1585 and EAI-1627 were minor (Table 2). However, to achieve 100% killing, especially for Beijing-1585, RIF concentrations had to be increased substantially (Table 2). Compared with the low-density culture for Beijing-1585, a substantial increase in RIF concentrations was needed to achieve 100% killing of the high-density culture (Table 2). This finding may be relevant in the clinical context because high-density mycobacteria populations are expected to exist in infected tissues of TB patients.
RIF-resistant mutants did not emerge in low-density cultures of Beijing-1585 and EAI-1627. However, RIF-resistant mutants were selected at relatively high numbers from high-density Beijing-1585 cultures compared with high-density EAI-1627 cultures. In Beijing-1585 cultures, exposure to RIF concentrations of 2-32 mg/L selected resistant mutants only; this was not observed in EAI-1627 cultures. Analysis of RIF-resistant Beijing mutants showed the following altered rpoB gene sequences: CAC [right arrow] GAC (H526D), CAC [right arrow] TAC (H526Y), and TCG [right arrow] TTG (S531L), as assessed by using the GenoType MTBDRplus (Hain Lifescience, Nehren, Germany) assay (for details, see the online Technical Appendix).
[FIGURE 1 OMITTED]
[FIGURE 2 OMITTED]
For 3 of the 4 anti-TB drugs, the difference in the range of mutant prevention concentrations for the Beijing and EAI genotype strains was small: INH, 128-256 mg/L; RIF, 256-1,024 mg/L; and MXF, 2-8 mg/L. The mutant prevention concentration for AMK was >1,024 mg/L for all strains tested.
We showed that the currently used anti-TB drug susceptibility assays do not discriminate between the in vitro susceptibility, as determined by the methods used in this study, of the M. tuberculosis Beijing and EAI genotype strains. We also showed that the determination of mutation frequencies might be more informative than results of anti-TB drug susceptibility assays. For RIF, mutation frequencies in Beijing genotype strains were high compared with those in EAI genotype strains, and the selection of RIF-resistant mutants among Beijing strains, but not EAI strains, occurred within a wide range of RIF concentrations. In addition, the killing capacity of RIF toward the Beijing genotype is dependent on the density of mycobacteria: high concentrations of RIF are required to achieve 100% killing of high-density Beijing genotype populations but not of high-density EAI genotype populations. These in vitro characteristics might contribute to the less favorable treatment outcome of Beijing genotype TB infections and their significant association with drug resistance. Our findings demonstrate the need for anti-TB drug treatments that will prevent resistance among M. tuberculosis Beijing genotype TB cases, and they suggest that the development of genotype-specific TB therapy might be justified.
We acknowledge RIVM for technical assistance and the National Institute of Hygiene and Epidemiology, Hanoi, Vietnam, and the Pham Ngoc Thach Tuberculosis and Lung Disease Hospital, Ho Chi Minh City, Vietnam, for sharing their M. tuberculosis isolates.
Financial support was provided by Erasmus University Medical Center and RIVM.
Dr de Steenwinkel is a medical doctor, resident in training for medical microbiologist, and a PhD student in clinical microbiology and antimicrobial therapy at Erasmus University Medical Center. His interests include research on improving therapy for TB and fundamental exploration of resistance formation.
(1.) World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response: 2010 global report on surveillance and response. 2010 Mar [cited 2011 Jun 11]. http://www.who.int/tb/publications/2010/978924599191/en/index.html
(2.) European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis. 2006;12:736-43. http://dx.doi.org/10.3201/eid1205.050400
(3.) Parwati I, van Crevel R, van Soolingen D. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect Dis. 2010;10:103-11. http://dx.doi.org/10.1016/S1473-3099(09)70330-5
(4.) Buu TN, Huyen MN, Lan NN, Quy HT, Hen NV, Zignol M, et al. Mycobacterium tuberculosis genotype and case notification rates, rural Vietnam, 2003-2006. Emerg Infect Dis. 2009;15:1570-7.
(5.) Buu TN, Huyen MN, Lan NT, Quy HT, Hen NV, Zignol M, et al. The Beijing genotype is associated with young age and multidrug-resistant tuberculosis in rural Vietnam. Int J Tuberc Lung Dis. 2009;13:900-6.
(6.) van der Spuy GD, Kremer K, Ndabambi SL, Beyers N, Dunbar R, Marais BJ, et al. Changing Mycobacterium tuberculosis population highlights clade-specific pathogenic characteristics. Tuberculosis (Edinb). 2009;89:120-5. http://dx.doi.org/10.1016/j. tube.2008.09.003
(7.) Anh DD, Borgdorff MW, Van LN, Lan NT, van Gorkom T, Kremer K, et al. Mycobacterium tuberculosis Beijing genotype emerging in Vietnam. Emerg Infect Dis. 2000;6:302-5. http://dx.doi. org/10.3201/eid0603.000312
(8.) Cowley D, Govender D, February B, Wolfe M, Steyn L, Evans J, et al. Recent and rapid emergence of W-Beijing strains of Mycobacterium tuberculosis in Cape Town, South Africa. Clin Infect Dis. 2008;47:1252-9. http://dx.doi.org/10.1086/592575
(9.) Lan NT, Lien HT. Tung le B, Borgdorff MW, Kremer K, van Soolingen D. Mycobacterium tuberculosis Beijing genotype and risk for treatment failure and relapse, Vietnam. Emerg Infect Dis. 2003;9:1633-5.
(10.) Hershberg R, Lipatov M, Small PM, Sheffer H, Niemann S, Homolka S, et al. High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biol. 2008;6:e311. http://dx.doi.org/10.1371/journal.pbio.0060311
(11.) National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard-second edition. CLSI document M24-A; 2011 [cited 2011 Feb 11]. http://www.clsi.org/source/orders/free/m24-a2.pdf
(12.) Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother. 2010;54:1484-91. http://dx.doi.org/10.1128/ AAC.01474-09
(13.) Ebrahimi-Rad M, Bifani P, Martin C, Kremer K, Samper S, Rauzier J, et al. Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family. Emerg Infect Dis. 2003;9:838-45.
(14.) Werngren J. Hoffner SE. Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate. J Clin Microbiol. 2003;41:1520-4. http://dx.doi.org/10.1128/JCM.41.4.1520-1524.2003
(15.) de Steenwinkel JE, de Knegt GJ, ten Kate MT, van Belkum A, Verbrugh HA, Kremer K, et al. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother. 2010;65:2582-9. http://dx.doi.org/10.1093/jac/dkq374
Author affiliations: Erasmus University Medical Center, Rotterdam, the Netherlands (J.E.M. de Steenwinkel, M.T. ten Kate, G.J. de Knegt, H.A. Verbrugh, I.A.J.M. Bakker-Woudenberg); National Institute of Public Health and the Environment Center for Infectious Disease Control (RIVM), Bilthoven, the Netherlands (K. Kremer, D. van Soolingen); World Health Organization Regional Office for Europe, Copenhagen, Denmark (K. Kremer); and Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands (R.E. Aarnoutse, M.J. Boeree, D. van Soolingen)
DOI: http://dx.doi.org/ 10.3201/eid1804.110912
Address for correspondence: Jurriaan E.M. de Steenwinkel, Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands; email: firstname.lastname@example.org
Table 1. Mutation frequency of Mycobacterium tuberculosis genotype strains originating from Vietnam, by antituberculosis drug Frequency of mutation among strains * Genotype Isoniazid Beijing 1585 5.7 x [10.sup.-6], 6.2 x [10.sup.-6] 1607 8.6 x [10.sup.-6], 1.4 x [10.sup.-5] 2115 7.3 x [10.sup.-6], 1.1 x [10.sup.-5] 2121 6.8 x [10.sup.-5], 2.9 x [10.sup.-4] 2145 9.1 x [10.sup.-4], 5.0 x [10.sup.-4] East-African/Indian 1627 3.7 x [10.sup.-6], 6.5 x [10.sup.-6] 1606 8.7 x [10.sup.-6], 1.6 x [10.sup.-4] 1592 1.8 x [10.sup.-5], 2.6 x [10.sup.-5] 1596 3.9 x [10.sup.-5], 2.8 x [10.sup.-5] 2113 1.3 x [10.sup.-5], 4.1 x [10.sup.-5] Frequency of mutation among strains * Genotype Rifampin Beijing 1585 3.0 x [10.sup.-3], 4.3 x [10.sup.-3] 1607 1.5 x [10.sup.-3], 5.4 x [10.sup.-3] 2115 1.0 x [10.sup.-3], 9.2 x [10.sup.-5] 2121 2.9 x [10.sup.-5], 1.9 x [10.sup.-4] 2145 1.6 x [10.sup.-5], 5.5 x [10.sup.-5] East-African/Indian 1627 4.1 x [10.sup.-6], 2.8 x [10.sup.-6] 1606 3.8 x [10.sup.-4], 2.7 x [10.sup.-5] 1592 3.0 x [10.sup.-4], 2.4 x [10.sup.-5] 1596 1.4 x [10.sup.-5], 3.9 x [10.sup.-6] 2113 6.7 x [10.sup.-8], 6.3 x [10.sup.-8] Frequency of mutation among strains * Genotype Moxifloxacin Beijing 1585 4.3 x [10.sup.-8], 6.1 x [10.sup.-8] 1607 6.9 x [10.sup.-8], 2.4 x [10.sup.-7] 2115 1.0 x [10.sup.-8], 4.3 x [10.sup.-8] 2121 1.1 x [10.sup.-7], 1.6 x [10.sup.-7] 2145 7.9 x [10.sup.-8], 1.0 x [10.sup.-7] East-African/Indian 1627 9.3 x [10.sup.-9], 1.5 x [10.sup.-7] 1606 3.2 x [10.sup.-8], 1.0 x [10.sup.-7] 1592 9.9 x [10.sup.-8], 4.5 x [10.sup.-8] 1596 1.7 x [10.sup.-7], 2.0 x [10.sup.-7] 2113 1.5 x [10.sup.-8], 1.0 x [10.sup.-7] Frequency of mutation among strains * Genotype Amikacin Beijing 1585 2.3 x [10.sup.-8], 3.2 x [10.sup.-8] 1607 8.6 x [10.sup.-8], 3.0 x [10.sup.-7] 2115 1.4 x [10.sup.-8], 2.8 x [10.sup.-8] 2121 9.3 x [10.sup.-8], 1.1 x [10.sup.-7] 2145 7.6 x [10.sup.-7], 1.1 x [10.sup.-6] East-African/Indian 1627 5.6 x [10.sup.-8], 4.5 x [10.sup.-9] 1606 7.5 x [10.sup.-9], 1.5 x [10.sup.-9] 1592 9.4 x [10.sup.-8], 1.5 x [10.sup.-9] 1596 3.7 x [10.sup.-8], 3.2 x [10.sup.-7] 2113 4.4 x [10.sup.-8], 3.3 x [10.sup.-7] * Determined in duplicate. Table 2. Concentration-and time-dependent bactericidal effect of rifampin toward Mycobacterium tuberculosis genotypes in low-and high-density cultures * Lowest RIF concentration resulting in killing of M. tuberculosis, mg/L Beijing-1585 genotype >99% killing 100% killing High High Low ([double Low ([double Day ([dagger]) dagger]) ([dagger]) dagger]) 1 8 ND 256 ND 3 1 0.008 64 1024 6 0.001 0.008 2 64 Lowest RIF concentration resulting in killing of M. tuberculosis, mg/L EAI-1627 genotype >99% killing 100% killing Low High Low High Day ([section]) ([paragraph]) ([section]) ([paragraph]) 1 8 ND 32 ND 3 0.125 0.03 8 32 6 0.001 0.06 1 2 * Cultures were exposed to RIF at 2-fold increasing concentrations for 6 days at 37[degrees]C; at indicated time-points, subcultures were performed on solid media for counting. Low, low-density culture; high, high-density culture; ND, not determined. ([dagger]) Density of 5.1 x [10.sup.5] CFU/mL. ([double dagger]) Density of 4.4 x [10.sup.6] CFU/mL. ([section]) Density of 6.8 x [10.sup.5] CFU/mL. ([paragraph]) Density of 3.0 x [10.sup.6] CFU/mL.
|Gale Copyright:||Copyright 2012 Gale, Cengage Learning. All rights reserved.|